Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

[BOON (Bonn ophthalmology online network). Concept of an integrative databank for monitoring patients under intravitreal therapy].

Milojcic C, Clemens CR, Fimmers R, Quade G, Alten F, Sarbach P, Eter N.

Ophthalmologe. 2014 Jan;111(1):37-43. doi: 10.1007/s00347-013-2823-0. German.

PMID:
23681179
2.

[Results of an expert survey on VEGF inhibitors in ophthalmology].

Kühn T.

Klin Monbl Augenheilkd. 2011 Jul;228(7):607-12. doi: 10.1055/s-0029-1245827. Epub 2011 Apr 6. German.

PMID:
21472638
3.

Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.

Funk M, Karl D, Georgopoulos M, Benesch T, Sacu S, Polak K, Zlabinger GJ, Schmidt-Erfurth U.

Ophthalmology. 2009 Dec;116(12):2393-9. doi: 10.1016/j.ophtha.2009.05.039. Epub 2009 Oct 7.

PMID:
19815292
4.

Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration.

Becerra EM, Morescalchi F, Gandolfo F, Danzi P, Nascimbeni G, Arcidiacono B, Semeraro F.

Curr Drug Targets. 2011 Feb;12(2):149-72. Review.

PMID:
20887246
5.

An epidemiological study of neovascular age-related macular degeneration in Germany.

Krause L, Yousif T, Pohl K; CAPTAIN study group.

Curr Med Res Opin. 2013 Oct;29(10):1391-7. doi: 10.1185/03007995.2013.832184. Epub 2013 Aug 23.

PMID:
23944372
6.

Anti-VEGF treatment patterns for neovascular age-related macular degeneration among medicare beneficiaries.

Lad EM, Hammill BG, Qualls LG, Wang F, Cousins SW, Curtis LH.

Am J Ophthalmol. 2014 Sep;158(3):537-43.e2. doi: 10.1016/j.ajo.2014.05.014. Epub 2014 May 21.

PMID:
24857687
7.

Early detection and treatment of neovascular age-related macular degeneration.

Bressler NM.

J Am Board Fam Pract. 2002 Mar-Apr;15(2):142-52. Review.

8.

Management of neovascular age-related macular degeneration.

Schmidt-Erfurth UM, Pruente C.

Prog Retin Eye Res. 2007 Jul;26(4):437-51. Epub 2007 Mar 27. Review.

PMID:
17512238
9.

Long-term follow-up for type 1 (subretinal pigment epithelium) neovascularization using a modified "treat and extend" dosing regimen of intravitreal antivascular endothelial growth factor therapy.

Engelbert M, Zweifel SA, Freund KB.

Retina. 2010 Oct;30(9):1368-75. doi: 10.1097/IAE.0b013e3181d50cbf. Erratum in: Retina. 2011 Jan;31(1):208.

PMID:
20517175
10.

Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.

Dunavoelgyi R, Sacu S, Eibenberger K, Palkovits S, Leydolt C, Pruente C, Schmidt-Erfurth U.

Retina. 2012 Sep;32(8):1471-9. doi: 10.1097/IAE.0b013e318236e805.

PMID:
22414958
11.
12.

Monitoring retinal function in neovascular maculopathy using multifocal electroretinography - early and long-term correlation with clinical findings.

Jurklies B, Weismann M, Hüsing J, Sutter EE, Bornfeld N.

Graefes Arch Clin Exp Ophthalmol. 2002 Apr;240(4):244-64. Epub 2002 Mar 15.

PMID:
11981638
13.

Efficacy of 12-month treatment of neovascular age-related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections.

Mekjavic PJ, Kraut A, Urbancic M, Lenassi E, Hawlina M.

Acta Ophthalmol. 2011 Nov;89(7):647-53. doi: 10.1111/j.1755-3768.2009.01740.x. Epub 2009 Oct 23.

14.

[Retinal angiomatous proliferation with associated pigment epithelium detachment: anti-VEGF therapy].

Lommatzsch A, Heimes B, Gutfleisch M, Spital G, Dietzel M, Pauleikhoff D.

Ophthalmologe. 2011 Mar;108(3):244-51. doi: 10.1007/s00347-010-2221-9. German.

PMID:
20571805
15.

Effects of intravitreal bevacizumab (Avastin) therapy on retrobulbar blood flow parameters in patients with neovascular age-related macular degeneration.

Mete A, Saygili O, Mete A, Bayram M, Bekir N.

J Clin Ultrasound. 2010 Feb;38(2):66-70. doi: 10.1002/jcu.20650.

PMID:
19953626
16.

Three-monthly intravitreal bevacizumab injections for neovascular age-related macular degeneration: short-term visual acuity results.

Ferraz D, Bressanim G, Takahashi B, Pelayes D, Takahashi W.

Eur J Ophthalmol. 2010 Jul-Aug;20(4):740-4.

PMID:
20155704
17.

[Anti-VEGF treatment for retinal angiomatous proliferation].

Wolf A, Kook D, Kreutzer T, Gandorfer A, Haritoglou C, Kampik A, Ulbig M.

Ophthalmologe. 2008 Sep;105(9):845-51. doi: 10.1007/s00347-008-1785-0. German.

PMID:
18607601
18.

[Guidance for the treatment of neovascular age-related macular degeneration (AMD)].

Karska-Basta I, Kubicka-Trzaska A, Oleksy P, Romanowska-Dixon B.

Przegl Lek. 2009;66(11):972-5. Review. Polish.

PMID:
20297641
19.

Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration.

Simader C, Ritter M, Bolz M, Deák GG, Mayr-Sponer U, Golbaz I, Kundi M, Schmidt-Erfurth UM.

Ophthalmology. 2014 Jun;121(6):1237-45. doi: 10.1016/j.ophtha.2013.12.029. Epub 2014 Mar 28.

PMID:
24684838
20.

Ranibizumab for retinal angiomatous proliferation in neovascular age-related macular degeneration.

Lai TY, Chan WM, Liu DT, Lam DS.

Graefes Arch Clin Exp Ophthalmol. 2007 Dec;245(12):1877-80. Epub 2007 Sep 28.

PMID:
17901972
Items per page

Supplemental Content

Write to the Help Desk